Combined immunosuppression with cyclosporine (Neoral) and SDZ RAD in non-human primate lung transplantation: Systematic pharmacokinetic-based trials to improve efficacy and tolerability

Transplantation

Volumn 69, Issue 1, 2000, Pages 76-86

  Hausen, Bernard ^a,d   Ikonen, T ^a   Briffa, N ^a   Berry, G J ^a   Christians, U ^a,b   Robbins, R C ^a   Hook, L ^a   Serkova, N ^b   Benet, L Z ^b   Schuler, W ^c   Morris, R E ^a,d  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; EVEROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; IMMUNOSUPPRESSIVE TREATMENT; LUNG BIOPSY; LUNG TRANSPLANTATION; MONKEY; NONHUMAN; PRIORITY JOURNAL;

EID: 0034650246     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200001150-00015     Document Type: Article

References (36)

1. Sibley RK, Berry GJ, Tazelaar HD, et al. The role of transbronchial biopsies in the management of lung transplant recipients. J Heart Lung Transplant 1993; 12: 308.
2. Trulock EP. Management of lung transplant rejection. Chest 1993; 103: 1566.
3. Bando K, Paradis IL, Similo S, et al. Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management. J Thorac Cardiovasc Surg 1995; 110: 4.
4. Schuurman HJ, Cottens S, Fuchs S, et al. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation 1997; 64: 32.
5. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997; 64: 36.
6. Appel Dingemanse S, Wong R, Dou L, et al. Multiple-dose pharmacokinetics of the immunosuppressant SDZ RAD in stable renal transplant patients. Transplantation 1998; 65: 138.
7. Morris RE. Rapamycins: antifungal, antitumor, antiproliferative, and immunosuppressive macrolides. Transplant Rev 1992; 6: 39.
8. Stepkowski SM, Napoli KL, Wang ME, Qu X, Chou TC, Kahan BD. Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. Transplantation 1996; 62: 986.
9. Stepkowski SM, Tian L, Napoli Kl, et al. Synergistic mechanisms by which sirolimus and cyclosporin inhibit rat heart and kidney allograft rejection. Clin Exp Immunol 1997; 108: 63.
10. Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol 1996; 14: 483.
11. Brazelton T, Morris RE. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr Opin Immunol 1996; 8: 710.
12. Billingham ME. Pathology of graft vascular disease after heart and heart-lung transplantation and its relationship to obliterative bronchiolitis. Transplant Proc 1995; 27: 2013.
13. Milne DS, Gascoigne A, Wilkes J, Sviland L, Ashcroft T. The immunohistopathology of obliterative bronchiolitis. Transplantation 1992; 54: 748.
14. Morris RE, Huang X, Gregory CR, et al. Studies in experimental models of chronic rejection: use of rapamycin (sirolimus) and isoxazole derivatives (leflunomide and its analogue) for the suppression of graft vascular disease and obliterative bronchiolitis. Transplant Proc 1995; 27: 2068.
15. Hausen B, Morris RE. Review of immunosuppression for lung transplantation. Novel drugs, new uses for conventional immunosuppressants, and alternative strategies. Clin Chest Med 1997; 18: 353.
16. Cao W, Mohacsi P, Shorthouse R, Pratt R, Morris RE. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation 1995; 59: 390.
17. Reichenspurner H, Huang X, Soni V, Shorthouse R, Berry GJ, Morris RE. Pathogenesis and treatment of obliterative airway disease after heterotopic tracheal allograft and xenograft transplantation. Surg Forum 1995; 46: 456.
18. Nair RV, Huang X, Shorthouse R, et al. Antiproliferative effect of rapamycin on growth factor-stimulated human adult lung fibroblasts in vitro may explain its superior efficacy for prevention and treatment of allograft obliterative airway disease in vivo. Transplant Proc 1997; 29: 614.
19. Lampen A, Zhang Y, Hackbarth I, Benet LZ, Sewing KF, Christians U. Metabolism and transport of the macrolide immuno-suppressant sirolimus in the small intestine. J Exp Pharmacol Ther 1998; 285: 1104.
20. Yacyshyn Br, Bowen-Yacyshyn MB, Pilarski LM. Inhibition by rapamycin of P-glycoprotein 170-mediated export from normal lymphocytes. Scand J Immunol 1996; 43: 449.
21. Hausen B, Boeke K, Berry GJ, Segarra I, Christians U, Morris RE. Suppression of acute rejection in allogeneic rat lung transplantation:A study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine. J Heart Lung Transplant 1998; 18: 150.
22. Schuurman HJ, Hengy JC, Ringers J, Vonderscher J, Schuler W, Jonker M. Neoral pharmacokinetics in cynomolgus monkeys: relation to efficacy in renal allografting. Transplant Proc 1996; 28: 3142.
23. Schuurman HJ, Schuler W, Ringers J, Jonker M. The macrolide SDZ RAD is efficacious in a nonhuman primate model of allotransplantation. Transplant Proc 1998; 30: 2198.
24. Cooper JD. Herbert Sloan lecture. Lung transplantation. Ann Thorac Surg 1989; 47: 28.
25. Streit F, Christians U, Scheibel HM, et al. Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray - mass spectrometry. Clin Chem 1996; 42: 1417.
26. Vidal C, Kirchner, GI, Wunsch G, Sewing KF. Automated simultaneous quantification of the immunosuppressants 40-O-(2-hydroxyethyl) rapamycin and cyclosporine in blood with electrospray mass spectrometric detection. Clin Chem 1998; 44: 1275.
27. Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 working formulation for the classification of. J Heart Lung Transplant 1996; 15: 1.
28. Kaplan B, MeierKriesche HU, Napoli K, Kahan BD. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. Clin Pharmacol Ther 1998; 63: 48.
29. Benet LZ, Wu CY, Herbert MF, Wacher VJ. Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery. J Control Release 1996; 39: 139.
30. Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdrl) in interpatient variation in the oral bio-availability of cyclosporine. Clin Pharmacol Ther 1997; 62: 248.
31. Whiting PH, Woo J, Adam BJ, Hasan NU, Davidson RJ, Thomson AW. Toxicity of rapamycin-a comparative and combination study with cyclosporine at immunotherapeutic dosage in the rat. Transplantation 1991; 52: 203.
32. Miller DS, Flicker G, Drewe J p-Glycoprotein-mediated transport of a fluorescent rapamycin derivative in renal proximal tubule. J Pharmacol Exp Ther 1997; 282: 440.
33. Zimmerman JJ, Kahan BD. Pharmacokinetics of Sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol 1997; 37: 405.
34. Griffith BP, Hardesty RL, Armitage JM, et al. Acute rejection of lung allografts with various immunosuppressive protocols. Ann Thorac Surg 1992; 54: 846.
35. Collier DS, Calne RY, Pollard SG, Friend PJ, Thiru S. Rapamycin in experimental renal allografts in primates. Transplant Proc 1991; 23: 2246.
36. Kahan BD. Concentration-controlled immunosuppressive regimens using cyclosporine with sirolimus or brequinar in human renal transplantation. Transplant Proc 1995; 27: 33.